Neurocrine Biosciences has announced that FDA has granted breakthrough therapy designation for NBI-98854 (Vesicular Monoamine Transporter 2 inhibitor) drug in tardive dyskinesia. A breakthrough therapy designation is granted for a drug that is intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on clinically significant endpoints over available therapies. ...
Read MoreYou have just read an article categorized health
titled NBI-98854 Drug Receives Breakthrough Designation for Tardive Dyskinesia.
Written by:
editor - Saturday, November 1, 2014
There are currently no comments for "NBI-98854 Drug Receives Breakthrough Designation for Tardive Dyskinesia"
Post a Comment